دورية أكاديمية
Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation.
| العنوان: | Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation. |
|---|---|
| المؤلفون: | Powell VE; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 110 Francis St. W/LMOB, Suite GB, Boston, MA, 02215, USA., Gibas KM; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 110 Francis St. W/LMOB, Suite GB, Boston, MA, 02215, USA., DuBow J; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 110 Francis St. W/LMOB, Suite GB, Boston, MA, 02215, USA., Krakower DS; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, 110 Francis St. W/LMOB, Suite GB, Boston, MA, 02215, USA. dkrakowe@bidmc.harvard.edu.; The Fenway Institute, Fenway Health, Boston, MA, USA. dkrakowe@bidmc.harvard.edu.; Department of Population Medicine, Harvard Medical School, Boston, MA, USA. dkrakowe@bidmc.harvard.edu. |
| المصدر: | Current infectious disease reports [Curr Infect Dis Rep] 2019 Jun 21; Vol. 21 (8), pp. 28. Date of Electronic Publication: 2019 Jun 21. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer US Country of Publication: United States NLM ID: 100888983 Publication Model: Electronic Cited Medium: Print ISSN: 1523-3847 (Print) Linking ISSN: 15233847 NLM ISO Abbreviation: Curr Infect Dis Rep Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: [New York] : Springer US Original Publication: Philadelphia, PA : Current Science, c1999- |
| مستخلص: | Purpose of Review: In 2019, the US government launched an initiative to decrease new HIV infections by 90% over the next decade. Studies have demonstrated the efficacy of HIV preexposure prophylaxis (PrEP) for high-risk populations, and the United States Preventative Services Task Force has issued a grade A recommendation for PrEP, indicating substantial net benefit. However, questions have been raised about the effectiveness of PrEP in clinical settings and whether PrEP use might promote antiretroviral drug resistance and increased sexual risk behaviors, which could increase transmission of bacterial sexually transmitted infections. In this narrative review, we summarize recent evidence of the effectiveness of PrEP when provided in clinical and community settings, the emergence of antiretroviral drug resistance during PrEP use, and associations between PrEP use and increased sexual risk behaviors. We also review novel PrEP modalities that are being developed to optimize PrEP acceptability, adherence, and effectiveness. Recent Findings: Studies suggest that PrEP is effective when provided in clinical settings. However, PrEP uptake and impact have been limited in the USA thus far, and major disparities in access to PrEP exist. In addition, there is evidence that drug resistance can occur with PrEP use, particularly with inadvertent PrEP use during undiagnosed acute HIV infection. Risk compensation can also occur with PrEP use and has been associated with increased sexually transmitted infections. Promising new modalities for PrEP could expand options. PrEP has strong potential to decrease HIV incidence. However, disparities in access must be addressed to ensure equity and impact for PrEP. While drug resistance and risk compensation can occur with PrEP use, these are not valid reasons to withhold PrEP from patients given its substantial protective benefits. |
| References: | AIDS. 2004 Mar 26;18(5):787-92. (PMID: 15075514) JAMA. 2004 Jul 14;292(2):224-36. (PMID: 15249572) BMJ. 2006 Mar 11;332(7541):605-7. (PMID: 16528088) N Engl J Med. 2010 Dec 30;363(27):2587-99. (PMID: 21091279) Sci Transl Med. 2011 Dec 7;3(112):112re4. (PMID: 22158861) N Engl J Med. 2012 Aug 2;367(5):399-410. (PMID: 22784037) N Engl J Med. 2012 Aug 2;367(5):423-34. (PMID: 22784038) AIDS Patient Care STDS. 2013 Apr;27(4):248-54. (PMID: 23565928) AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50. (PMID: 23600365) Lancet. 2013 Jun 15;381(9883):2083-90. (PMID: 23769234) PLoS One. 2013 Dec 18;8(12):e81997. (PMID: 24367497) AIDS Behav. 2014 Sep;18(9):1712-21. (PMID: 24965676) AIDS Behav. 2015 May;19(5):802-10. (PMID: 25616837) AIDS Educ Prev. 2015 Apr;27(2):112-25. (PMID: 25915697) Curr Treat Options Infect Dis. 2015 Jun;7(2):101-112. (PMID: 25931990) Clin Infect Dis. 2015 Nov 15;61(10):1601-3. (PMID: 26334052) Curr Opin HIV AIDS. 2016 Jan;11(1):41-8. (PMID: 26417953) Lancet HIV. 2015 Dec;2(12):e512-9. (PMID: 26614965) N Engl J Med. 2015 Dec 3;373(23):2237-46. (PMID: 26624850) N Engl J Med. 2016 Dec;375(22):2121-2132. (PMID: 26900902) J Infect Dis. 2016 Jul 1;214(1):55-64. (PMID: 26917574) AIDS. 2016 Jul 31;30(12):1985-90. (PMID: 27149088) AIDS. 2016 Jul 31;30(12):1973-83. (PMID: 27149090) AIDS Patient Care STDS. 2016 Jun;30(6):282-90. (PMID: 27220036) Clin Infect Dis. 2016 Sep 1;63(5):672-7. (PMID: 27282710) PLoS One. 2016 Jun 22;11(6):e0157742. (PMID: 27333000) Sex Transm Infect. 2017 Feb;93(1):52-55. (PMID: 27356041) AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):981-991. (PMID: 27526873) J Adolesc Health. 2016 Dec;59(6):725-728. (PMID: 27720357) J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608. (PMID: 27846073) J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546. (PMID: 27851714) AIDS Behav. 2017 May;21(5):1256-1267. (PMID: 27885552) N Engl J Med. 2016 Dec;375(22):2133-2143. (PMID: 27959766) Sci Rep. 2017 Feb 01;7:41098. (PMID: 28145472) N Engl J Med. 2017 Feb 2;376(5):501-502. (PMID: 28146652) AIDS Behav. 2018 Apr;22(4):1075-1079. (PMID: 28150120) AIDS Patient Care STDS. 2017 Apr;31(4):196-204. (PMID: 28414261) Lancet HIV. 2017 Oct;4(10):e449-e456. (PMID: 28732773) Lancet HIV. 2017 Sep;4(9):e402-e410. (PMID: 28747274) Curr HIV/AIDS Rep. 2017 Oct;14(5):153-160. (PMID: 28812207) AIDS Educ Prev. 2017 Aug;29(4):315-329. (PMID: 28825858) Lancet HIV. 2017 Nov;4(11):e522-e528. (PMID: 28919303) AIDS Care. 2018 May;30(5):650-655. (PMID: 28971705) Curr HIV/AIDS Rep. 2017 Dec;14(6):201-210. (PMID: 29071519) J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106. (PMID: 29076941) J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):358-364. (PMID: 29210834) AIDS. 2018 Feb 20;32(4):523-530. (PMID: 29239887) AIDS Behav. 2018 Apr;22(4):1096-1099. (PMID: 29243109) AIDS. 2018 Mar 27;32(6):687-698. (PMID: 29424773) Sex Transm Dis. 2018 Jul;45(7):452-458. (PMID: 29465664) Kans J Med. 2017 May 15;10(2):40-42. (PMID: 29472966) Nat Med. 2018 May;24(4):491-496. (PMID: 29480895) Clin Infect Dis. 2018 Aug 16;67(5):676-686. (PMID: 29509889) AIDS. 2018 Jun 1;32(9):F1-F4. (PMID: 29683856) LGBT Health. 2018 May/Jun;5(4):250-256. (PMID: 29688800) AIDS. 2018 Jul 17;32(11):1527-1532. (PMID: 29762169) Ann Epidemiol. 2018 Dec;28(12):850-857.e9. (PMID: 29941379) Clin Infect Dis. 2018 Aug 31;67(6):962-964. (PMID: 29961859) J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):186-194. (PMID: 29975211) Can J Public Health. 2018 Jun;109(3):342-352. (PMID: 29981088) Can J Public Health. 2018 Dec;109(5-6):791-799. (PMID: 29981103) Ann Epidemiol. 2018 Dec;28(12):841-849. (PMID: 29983236) Clin Infect Dis. 2019 Feb 15;68(5):860-864. (PMID: 30020422) AIDS Care. 2019 May;31(5):536-544. (PMID: 30304942) MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150. (PMID: 30335734) Lancet HIV. 2018 Nov;5(11):e629-e637. (PMID: 30343026) J Infect Dis. 2019 Apr 16;219(9):1373-1376. (PMID: 30462305) Lancet HIV. 2018 Nov 29;:. (PMID: 30503324) J Int AIDS Soc. 2019 Feb;22(2):e25250. (PMID: 30768762) Clin Infect Dis. 2019 Apr 09;:null. (PMID: 30963179) Drugs. 2019 Apr;79(6):609-619. (PMID: 30963509) JAMA. 2019 Apr 9;321(14):1380-1390. (PMID: 30964528) Nat Commun. 2019 May 1;10(1):2005. (PMID: 31043606) Lancet HIV. 2019 Jul 5;:null. (PMID: 31285182) Lancet HIV. 2019 Jul 5;:null. (PMID: 31285183) |
| معلومات مُعتمدة: | P30 AI060354 United States AI NIAID NIH HHS; P30 AI060354 United States NH NIH HHS |
| فهرسة مساهمة: | Keywords: Clinical effectiveness; Drug resistance; HIV; Preexposure prophylaxis; Risk compensation |
| تواريخ الأحداث: | Date Created: 20190623 Latest Revision: 20211203 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8635937 |
| DOI: | 10.1007/s11908-019-0685-6 |
| PMID: | 31227999 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1523-3847 |
|---|---|
| DOI: | 10.1007/s11908-019-0685-6 |